Арилжаа Takeda Pharmaceutical Company Limited - 4502 CFD

Арилжааны нөхцөл

• Төрөл: CFD
• Спред: 17.12
• Лонг позицын шөнийн санхүүжилтийн тохируулга: -0.01305%
• Шорт позицын нэг шөнийн санхүүжилтийн тохируулга: -0.00917%
• Шөнийн санхүүжилтийг тохируулах хугацаа: 22:00 (UTC)
• Валют: JPY
• Арилжаалсан доод хэмжээ: 1
• Маржин: 5.00%
• Хөрөнгийн бирж: Japan
• Арилжааны шимтгэл: 0%
• Баталгаат стопын шимтгэл: 1%

Гол үзүүлэлтүүд

• Өмнөх Хаах: 5097.99
• Нээх: 5058.83
• 1 жилийн өөрчлөлт: 25.31%
• Өдрийн диапазон: 5041.84 - 5058.83

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS to uncover novel tumor-specific regulatory t-cell targets and develop unique anti-suppressor-based immunotherapies; a strategic partnership with Neurocrine Biosciences, Inc. to develop and commercialize therapies for psychiatric disorders; and Carmine Therapeutics to discover, develop, and commercialize transformative non-viral gene therapies for two rare diseases. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.